Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Making The Most Of Pre-Submission Meetings: FDA Discusses Best Practices

This article was originally published in The Gray Sheet

Executive Summary

FDA's device center hopes upcoming guidance on pre-submission interactions will cut down on inconsistencies in how various divisions handle these FDA-industry meetings.

You may also be interested in...



Citizen Petition: FDA Reneged On Binding Agreement For Melanoma Device

Mela Sciences has filed a citizen petition asking FDA Commissioner Margaret Hamburg to enforce a “binding protocol agreement” and investigate regulators’ conduct as the company struggles to obtain PMA approval for its MelaFind melanoma detection device.

Industry Experts Debate Impact Of FDA's Upcoming Pre-IDE Guidance

Device industry experts expressed mixed views on the impact upcoming pre-IDE draft guidance would have on early interactions between industry and FDA at a recent conference in Cincinnati.

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.

 

UsernamePublicRestriction

Register

MT030242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel